Design, synthesis and biological evaluation of novel non-covalent piperidine-containing peptidyl proteasome inhibitors.

A series of novel non-covalent piperidine-containing dipeptidyl derivatives were designed, synthesized and evaluated as proteasome inhibitors. All target compounds were tested for their proteasome chymotrypsin-like inhibitory activities, and selected derivatives were evaluated for the anti-proliferation activities against two multiple myeloma (MM) cell lines RPMI 8226 and MM-1S. Among all of these compounds, eight exhibited significant proteasome inhibitory activities with IC50 less than 20nM, and four are more potent than the positive control Carfilzomib. Compound 28 displayed the most potent proteasome inhibitory activity (IC50: 1.4±0.1nM) and cytotoxicities with IC50 values at 13.9±1.8nM and 9.5±0.5nM against RPMI 8226 and MM-1S, respectively. Additionally, the ex vivo blood cell proteasome inhibitory activities of compounds 24 and 27-29 demonstrated that the enzymatic metabolism in the whole blood could be well tolerated. All these experiments confirmed that the piperidine-containing non-covalent proteasome inhibitors are potential leads for exploring new anti-cancer drugs.

[1]  M. Shirley.  Ixazomib: First Global Approval , 2016, Drugs.

[2]  Jonathan L Blank,et al.  Optimization of a series of dipeptides with a P3 threonine residue as non-covalent inhibitors of the chymotrypsin-like activity of the human 20S proteasome. , 2010, Bioorganic & medicinal chemistry letters.

[3]  R. Orlowski,et al.  The proteasome and proteasome inhibitors in cancer therapy. , 2006, Annual review of pharmacology and toxicology.

[4]  Yongzhou Hu,et al.  Clinical and marketed proteasome inhibitors for cancer treatment. , 2013, Current medicinal chemistry.

[5]  D. Kuhn,et al.  Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade , 2008, Clinical Cancer Research.

[6]  Aaron Ciechanover,et al.  The ubiquitin-proteasome proteolytic pathway , 1994, Cell.

[7]  J. Adams.  The proteasome: a suitable antineoplastic target , 2004, Nature Reviews Cancer.

[8]  Aaron Ciechanover,et al.  The ubiquitin–proteasome pathway: on protein death and cell life , 1998, The EMBO journal.

[9]  P. Furet,et al.  Entry into a new class of potent proteasome inhibitors having high antiproliferative activity by structure-based design. , 2004, Journal of medicinal chemistry.

[10]  A. Goldberg,et al.  Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. , 2006, Journal of the American Society of Nephrology : JASN.

[11]  H. Ploegh,et al.  Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. , 2006, Structure.

[12]  R. Pazdur,et al.  U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma , 2013, Clinical Cancer Research.

[13]  Yili Yang,et al.  Targeting the ubiquitin‐proteasome system for cancer therapy , 2009, Cancer science.

[14]  R. Gavioli,et al.  C-terminal constrained phenylalanine as a pharmacophoric unit in peptide-based proteasome inhibitors. , 2008, European journal of medicinal chemistry.

[15]  T. Soucy,et al.  Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β5-subunit , 2010, The Biochemical journal.

[16]  Synthesis of amino acid ester isocyanates: Methyl (S)-2-isocyanato-3-phenylpropanoate (benzenepropanoic acid, α-isocyanato-, methyl ester, (S)) , 2002 .

[17]  A. Ciechanover,et al.  The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. , 2002, Physiological reviews.

[18]  J. Sacchettini,et al.  Crystal structure of the human 20S proteasome in complex with carfilzomib. , 2015, Structure.

[19]  Maurizio Fermeglia,et al.  Synthesis, biological evaluation, and three-dimensional in silico pharmacophore model for sigma(1) receptor ligands based on a series of substituted benzo[d]oxazol-2(3H)-one derivatives. , 2009, Journal of medicinal chemistry.

[20]  Richard Pazdur,et al.  Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. , 2003, The oncologist.

[21]  M. Groll,et al.  Covalent and non-covalent reversible proteasome inhibition , 2012, Biological chemistry.

[22]  V. Tsui,et al.  Inhibiting the deubiquitinating enzymes (DUBs). , 2015, Journal of medicinal chemistry.

[23]  J. Wade Harper,et al.  Drug discovery in the ubiquitin–proteasome system , 2006, Nature Reviews Drug Discovery.

[24]  J. Adams,et al.  The proteasome: structure, function, and role in the cell. , 2003, Cancer treatment reviews.